Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment
Not yet recruiting
Assistance Publique - Hôpitaux de Paris
Phase 1/Phase 2
2022-10-01
Acute myeloid leukemia (AML) is a heterogeneous clonal myeloid neoplasm where abnormal
proliferation and impaired differentiation of hematopoietic stem and myeloid progenitor cells
impedes normal hematopoiesis. Sulfasalazine (SSZ) is a broadly available, well tolerated
anti-inflammatory medicine approved for the treatment of ulcerative colitis and rheumatoid
arthritis. Intact SSZ, but not its metabolites 5-aminosalicylic acid and sulfapyridine,
competitively inhibits xCT.21 SSZ is thus an ideal candidate for drug repurposing in AML.The
purpose of this phase I study is to evaluate the safety and feasibility of such strategy,
provide preliminary signals of efficacy, and identify potential biomarkers
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
